Ibogaine vs Psilocybin

Ibogaine vs psilocybin is a comparison that comes up when someone is looking for a psychedelic approach to a serious condition and wants to understand which drug fits which problem. The short answer: they are not interchangeable. They work differently, carry different risks, and have different evidence bases. This guide walks through every key dimension side by side.

Quick answer: ibogaine vs psilocybin

Ibogaine is the psychedelic with the strongest signal for interrupting opioid addiction. One session can dramatically reduce withdrawal symptoms and cravings. But it requires medical oversight, cardiac screening, and international travel because it is not legal anywhere in the US. Psilocybin is the better-studied option for depression and anxiety. It is available legally in Oregon and Colorado, and it carries a much lower safety burden. For most people considering psychedelic therapy today, psilocybin is the easier path unless addiction — specifically opioid use disorder — is the primary goal.

Ibogaine vs psilocybin: side-by-side comparison

How ibogaine and psilocybin work

Ibogaine is derived from the Tabernanthe iboga shrub, native to Central Africa, where it has been used ceremonially by the Bwiti tradition for centuries. Pharmacologically, it is unusually complex. It acts simultaneously on multiple receptor systems: it blocks the NMDA glutamate receptor (like ketamine), it is an agonist at kappa-opioid and sigma-1 receptors, and it activates serotonin 5-HT_2A receptors (like psilocybin). Its active metabolite, noribogaine, lasts in the body for days and may account for much of the lasting anti-addictive effect. The net experience is distinct from every other psychedelic: deeply visual and introspective, with a waking-dream quality, often described as a "life review."

Psilocybin is a prodrug that converts in the body to psilocin, which binds primarily to 5-HT_2A serotonin receptors. This mechanism is what it shares with LSD, DMT, and mescaline — it is a "classic" psychedelic. Read our full psilocybin guide for the science in depth. The key result at the brain level is a temporary disruption of the default mode network, which many researchers believe allows rigid negative thought patterns to loosen. Effects last 4–8 hours and then resolve completely.

The practical difference is experience length and target receptor. Ibogaine's multi-receptor action — particularly its interaction with opioid receptors — is thought to explain why it can interrupt opioid withdrawal in a way psilocybin does not.

What the evidence shows

Ibogaine for opioid use disorder

Ibogaine produces some of the most striking single-session results in addiction medicine. A 2021 Stanford-led observational study (Mash et al.) found that a single ibogaine session substantially reduced opioid and cocaine use in participants at 30 days post-treatment.¹ A 2024 randomized controlled trial published in Nature Medicine by Borger et al., conducted in veterans with TBI and PTSD, showed significant reductions in PTSD, depression, and disability scores one month after a single ibogaine session under medical supervision.² However, neither trial is a Phase 3 registration study. The FDA has granted ibogaine a Breakthrough Therapy designation for opioid use disorder but has not approved it.

Psilocybin for depression and anxiety

Psilocybin has more advanced clinical data in its key indication. In 2025, COMPASS Pathways reported positive Phase 3 trial results for COMP360 psilocybin in treatment-resistant depression, with statistically significant improvement on the MADRS scale at week three compared to placebo.³ Johns Hopkins and NYU have also published Phase 2 trial results showing large effect sizes for psilocybin in depression and cancer-related anxiety.⁴ Psilocybin holds Breakthrough Therapy designation from the FDA for both treatment-resistant depression and major depressive disorder. It is not yet approved.

Where ibogaine and psilocybin overlap

Both substances have early data in addiction beyond their primary indication. Psilocybin has shown promise for alcohol and tobacco use disorder in small trials. Ibogaine has open-label data in heroin, cocaine, and alcohol use. Neither has been compared head-to-head in a randomized trial for addiction.

Legal status: why access looks so different

Both ibogaine and psilocybin are Schedule I controlled substances in the United States. However, the policy landscape has diverged sharply.

Psilocybin has carved out two legal pathways: Oregon's Measure 109 (service centers operational since 2023) and Colorado's Proposition 122 (healing centers licensing in 2025). Adults can legally purchase and use psilocybin at licensed facilities in those states without a prescription. Dozens of states are considering similar measures. Check our guide to psychedelic legal status in the US for the current map.

Ibogaine has no equivalent state-level pathway. No US state has created a regulated access program for ibogaine. The only legal US access is through FDA-authorized investigational new drug (IND) clinical trials, which are limited in capacity and not a practical option for most people. Read the full ibogaine guide for more on the current IND landscape.

For most people, access to ibogaine means booking a vetted international clinic. Mexico, Portugal, and Costa Rica are the most common destinations. See our roundup of ibogaine treatment centers for what to look for in a clinic.

Safety comparison: ibogaine vs psilocybin

Ibogaine cardiac risk — the most important safety fact

Ibogaine prolongs the QT interval on an electrocardiogram. A prolonged QT interval increases the risk of torsades de pointes, a type of ventricular arrhythmia that can be fatal. Deaths have been reported in ibogaine sessions, and most are linked to cardiac events in people who were not screened for pre-existing QT prolongation or structural heart disease.⁵

This is why reputable ibogaine clinics require a 12-lead EKG and full cardiac workup before admission, why IV access and cardiac monitoring equipment are present during the session, and why certain medications (especially those that also prolong QT — many SSRIs, antipsychotics, antihistamines) must be cleared before dosing. Non-negotiable. This is not a "precaution" — it is a prerequisite.

Psilocybin safety profile

Psilocybin has a much lower physiological risk profile in screened patients. There are no documented deaths from psilocybin's direct pharmacology in clinical trials. Blood pressure and heart rate rise modestly during a session. The main risks are psychological: anxiety, panic, difficult emotional experiences, and — in rare cases in people with a personal or family history of psychosis — a brief psychotic episode. Read our psychedelic medication safety guide for drug interactions and screening considerations.

Drug interactions

Ibogaine interacts dangerously with opioids (including the opioids the person is trying to stop using), stimulants, and many psychiatric medications. Proper washout periods are critical. Psilocybin interacts with serotonergic medications — SSRIs and SNRIs blunt the effect, while MAOIs intensify it (see our ayahuasca guide for MAOI detail).

Cost and access compared

• Ibogaine: Vetted international clinics charge roughly $3,000–$8,000 for a full program including medical screening, the session itself, and at least 24–48 hours of post-session monitoring. Travel and accommodation add to that. Some programs run $12,000+ for luxury facilities.
• Psilocybin: A single legal session in Oregon or Colorado typically runs $1,000–$3,500 all-in, depending on the service center. No travel required if you are based in or willing to travel to either state. Sessions in Jamaica or the Netherlands cost similarly.

Integration therapy is important after either treatment. Factor in the cost of follow-up sessions with a therapist trained in psychedelic integration — typically $100–$300 per session. Find an integration therapist through our therapist finder.

The verdict: ibogaine vs psilocybin — which is right for you?

Choose ibogaine if opioid use disorder is your primary goal and you are prepared for the rigors: medical screening, international travel, a 36+ hour experience, and careful integration afterward. The addiction-interruption signal is unlike anything else in psychedelic medicine. Only go to a clinic with documented cardiac screening protocols and on-site medical monitoring.

Choose psilocybin if your primary goal is depression, anxiety, existential distress, or general psychological growth. The evidence base is stronger, the safety profile is more manageable, and legal access exists in Oregon and Colorado without international travel. It is also a shorter, less demanding experience.

Not sure which psychedelic path fits your situation? Try our which psychedelic quiz for a personalized starting point, or use the retreat finder to compare center options.